EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

EEDGAR/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Groups
  • Trending
  • News

More

  • Pricing
  • Community
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice. EDGAR is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. EDGAR/calls is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Pulling SEC filings + quote and writing the call…

EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity
← New search
Home›Stocks›SRZN

SRZN

Surrozen, Inc./DE

Next earnings Aug 7, 2026 · consensus $-1.31 EPS, $477K rev

Last earnings +4.6% on 2026-05-06

Avoid
$25.22
▲ +2.85%
$25.22▲ +179.60%
over 1Y
L $8.29EODHDH $34.13
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+2.9%
1W+6.6%
1M-4.7%
3M-12.7%
YTD+17.0%
1Y+179.6%
OverviewFinancialsValuationQualityTimelineFilings
Rating
Avoid
Quality
F
Valuation
Fair value
Filings
Watch
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 11 analysts
Buy

Conservative balance sheet (liabilities/equity -1.53x); but revenue fell -67.4% YoY.

Revenue (FY2025) $3.48M · FY2025

Surrozen, Inc./DE shows $3.48M in FY2025 revenue (-67.4% YoY), a -6960.8% net margin.

Financials · annual, by fiscal year

Line itemFY21FY22FY23FY24FY25
Revenue——$0.00$10.7M$3.48M
Gross profit—————
Operating income-$54.4M-$44.3M-$45.8M-$25.5M-$42.1M
Net income-$54.6M-$36.0M-$43.0M-$63.6M-$242M
Diluted EPS-$2.21-$15.56-$21.33-$21.67-$32.37
Net margin———-596.6%-6960.8%

Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.

Key statistics

Valuation

Enterprise value$200M
EV / EBITDA—
EV / Sales57.7
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-83.5%
FCF yield-10.5%

Quality & risk

ROIC (est.)—
Free cash flow-$30.4M
Total debt—
Net cash$89.2M
Altman Z-Score-7.25 distress
Piotroski F-Score2/7

Capital returns

Buyback yield0.0%
Dividend yield (est.)—
Shareholder yield0.0%
Shares Δ YoY+250.1%

Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.

Disclosure timeline

SEC · 8-Ks + reports
Some governance/structural items recently, but no outright red flags.
  1. 8-K Shareholder vote2026-05-14
  2. 8-K Earnings results2026-05-06
  3. 10-Q Quarterly report2026-05-06
  4. DEF 14A Proxy statement2026-04-01
  5. 8-K Earnings results2026-03-23
  6. S-3 Shelf registration (potential raise)2026-03-23
  7. 10-K Annual report2026-03-23
  8. 8-K Officer / director change2026-01-30
  9. 8-K Officer / director change2025-11-07

Recent filings

all on EDGAR ↗
4Period ending 2026-06-152026-06-16open ↗4Period ending 2026-06-152026-06-16open ↗4Period ending 2026-06-152026-06-16open ↗4Period ending 2026-06-152026-06-16open ↗4Period ending 2026-05-132026-05-19open ↗SCHEDULE 13D/AFiling2026-05-18open ↗SCHEDULE 13G/AFiling2026-05-15open ↗SCHEDULE 13G/AFiling2026-05-15open ↗SCHEDULE 13G/AFiling2026-05-15open ↗SCHEDULE 13G/AFiling2026-05-15open ↗SCHEDULE 13GFiling2026-05-15open ↗SCHEDULE 13G/AFiling2026-05-15open ↗

Quality score

F
ValueGrowthProfitHealthMom.
ValueF
GrowthF
ProfitabilityF
Financial healthF
Momentum—
  • ✗Revenue growing year-over-year
  • ✗Profitable (positive net income)
  • ✗Net margin above 10%
  • ✓Liabilities below 2× equity
Revenue
$3.48M
-67.4% YoY
Net margin
-6960.8%
ROE
—
P/E
—

SEC fundamentals · FY 2025

'21'22'23'24'25

■ revenue · ■ net income, by fiscal year

Revenue$3.48M-67.4%
Net income-$242M-280.8%
Operating income-$42.1M-64.8%
Diluted EPS-$32.37-49.4%
Cash & equivalents$89.2M+158.2%
Total assets$98.7M+103.7%
Total liabilities$286M+310.2%
Stockholders' equity-$188M-778.2%
Op.: -1210.6%L/E: -1.53x

Frequently asked

Is Surrozen, Inc./DE (SRZN) a buy?
SRZN currently carries a Avoid rating with 4/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity -1.53x); but revenue fell -67.4% YoY.
What is Surrozen, Inc./DE's quality score?
SRZN scores 18.941176470588236/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.

Sources: SEC EDGAR (CIK 0001824893, latest 10-Q filed 2026-05-06) · EODHD · as of 6/26/2026, 8:17:50 PM.

Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.

Insider activity

Form 4 · SEC
2026-06-15
Maleki Andrew Pedrum
Chief Financial Officer
Award607.00 @ $19.01$11.5K
2026-06-15
Li Yang
Exec. Vice President, Research
Award1.67K @ $8.11$13.5K
2026-06-15
Williams Charles O
Chief Operating Officer
Award1.67K @ $8.11$13.5K
2026-06-15
Parker Craig C
Chief Executive Officer
Award1.62K @ $8.11$13.2K

Earnings history

beat/miss · move
2026-05-06Miss -946.0% est▲ +4.56%8-K ↗
2026-03-23—▲ +0.36%8-K ↗
2025-11-07Miss -622.1% est▼ -2.40%8-K ↗
2025-08-08Beat +325.2% est▲ +5.87%8-K ↗
2025-05-09Miss -308.1% est▼ -3.90%8-K ↗
2025-03-31Miss -308.1% est▲ +5.90%8-K ↗

Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.

Recent news

market news →
Surrozen to Present at Upcoming Healthcare Investor ConferenceBullish
globenewswire.com· 2026-05-12
Surrozen (SRZN) Surges 5.9%: Is This an Indication of Further Gains?Bullish
finance.yahoo.com· 2026-04-14
Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Bullish
globenewswire.com· 2026-02-23
Surrozen to Present at Upcoming Healthcare Investor ConferencesBullish
globenewswire.com· 2025-11-25
Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Bullish
globenewswire.com· 2025-11-12
Surrozen GAAP EPS of $0.00, revenue of $6.97M
seekingalpha.com· 2025-11-10

Vs tracked universe

compare →

1043 tracked peers · median

EDGAR Score19 vs 67
Revenue growth-67.4% vs 7.1%
Net margin-6960.8% vs 10.5%
Return on equity— vs 12.3%
P/E— vs 25.5